Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass?
Peeters et al., 20081
Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium
Primary patency of GORE® PROPATEN® Vascular Graft
Patient characteristics
Characteristic | N | % |
---|---|---|
Rutherford classification† | ||
3 | 85 | 56% |
4 | 29 | 19% |
5 | 39 | 25% |
Runoff Vessels† | 10 | 3% |
0 | 7 | 5% |
1 | 76 | 50% |
2 | 43 | 28% |
3 | 27 | 18% |
Diabetes† | 37 | 27% |
Hypertension* | 88 | 64% |
Coronary artery disease* | 42 | 30% |
Nicotine use* | 66 | 48% |
Study details
- Prospective, multi-center study
- No adjunctive techniques (patches or cuffs) were used in the study
- 73% of patients had been previously treated for peripheral vascular disease (PVD)
- The 3-year limb salvage rate for all CLI patients was 86%**
…it is our opinion that the Propaten Vascular Graft [GORE® PROPATEN® Vascular Graft] may succeed in bridging the gap between venous conduits and regular ePTFE grafts. — P. Peeters
* Total N = 138, which includes 97 patients that underwent below-knee bypasses.
** Limb salvage rates are for both above and below-knee bypasses.
† Total N = 153 limbs
1. Peeters P, Verbist J, Deloose K, Bosiers M. Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass? Italian Journal of Vascular & Endovascular Surgery 2008;15(3):143-148.